Advertisement
Canada markets open in 3 hours 54 minutes
  • S&P/TSX

    21,871.96
    +64.59 (+0.30%)
     
  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     
  • DOW

    38,239.98
    +253.58 (+0.67%)
     
  • CAD/USD

    0.7296
    -0.0005 (-0.07%)
     
  • CRUDE OIL

    82.21
    +0.31 (+0.38%)
     
  • Bitcoin CAD

    90,840.20
    +352.39 (+0.39%)
     
  • CMC Crypto 200

    1,423.05
    +8.29 (+0.59%)
     
  • GOLD FUTURES

    2,307.50
    -38.90 (-1.66%)
     
  • RUSSELL 2000

    1,967.47
    +19.82 (+1.02%)
     
  • 10-Yr Bond

    4.6230
    +0.0080 (+0.17%)
     
  • NASDAQ futures

    17,391.25
    +41.25 (+0.24%)
     
  • VOLATILITY

    16.69
    -0.25 (-1.48%)
     
  • FTSE

    8,046.79
    +22.92 (+0.29%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • CAD/EUR

    0.6837
    -0.0013 (-0.19%)
     

Novartis’s Valuation and Analysts’ Recommendations on April 11

Novartis’s Valuation and Analysts’ Recommendations on April 11

Novartis AG (NVS) reported EPS (earnings per share) of $1.21 on revenue of ~$12.9 billion in 4Q17, a 5% rise compared to $12.3 billion in 4Q16. Novartis is expected to report revenue of $12.5 billion in 1Q18 compared to $11.5 billion in 1Q17. On April 11, 2018, Novartis was trading at a forward PE of ~14.9x.